Seaport Therapeutics (SPTX) General Counsel lists option and Series B preferred stakes
Rhea-AI Filing Summary
Seaport Therapeutics, Inc. General Counsel Lana Gladstein filed an initial ownership report showing derivative stakes in Seaport’s equity. She holds stock options linked to 63,680, 26,533 and 246,760 shares of common stock at exercise prices of $10.31, $7.39 and $3.05 per share, expiring between 2034 and 2036. She also holds Series B Preferred Stock convertible into 33,515 common shares on a one-for-3.1407 basis, which automatically converts into common stock upon the company’s initial public offering without additional payment. Footnotes explain that one option grant is fully vested, while the others vest over four years in monthly installments, contingent on her continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Gladstein Lana
Role
General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series B Preferred Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Series B Preferred Stock — 33,515 shares (Direct);
Stock Option (Right to Buy) — 336,973 shares (Direct)
Footnotes (1)
- Each share of Series B Preferred Stock (the "Preferred Stock") is convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares shown in Column 3 without payment of further consideration. The Preferred Stock has no expiration date. 1/4th of the shares underlying this option vested and became exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each vesting date. The shares underlying this option are fully vested and exercisable. The shares underlying this option shall vest in forty-eight (48) equal monthly installments following February 24, 2026, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Option underlying shares: 63,680 shares
Option underlying shares: 26,533 shares
Option underlying shares: 246,760 shares
+4 more
7 metrics
Option underlying shares
63,680 shares
Stock Option (Right to Buy), exercise price $10.31, expires 2036-02-23
Option underlying shares
26,533 shares
Stock Option (Right to Buy), exercise price $7.39, expires 2034-12-28
Option underlying shares
246,760 shares
Stock Option (Right to Buy), exercise price $3.05, expires 2034-06-03
Series B underlying shares
33,515 shares
Series B Preferred Stock convertible into common stock, no expiration date
Conversion ratio
1 : 3.1407
Each Series B Preferred share convertible into 3.1407 common shares
Vesting start date
June 6, 2025
One-quarter of option vested then; remainder in 36 monthly installments
Second vesting schedule
48 monthly installments
Option vesting following February 24, 2026, subject to continued service
Key Terms
Stock Option (Right to Buy), Series B Preferred Stock, initial public offering, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"The security title for several entries is Stock Option (Right to Buy)."
Series B Preferred Stock financial
"One holding is Series B Preferred Stock convertible into common stock."
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
initial public offering financial
"Preferred Stock will automatically convert upon the closing of the Issuer's initial public offering."
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
vesting financial
"Shares underlying this option vested and became exercisable and vest in monthly installments."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"Each stock option lists a conversion or exercise price per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Lana Gladstein report owning in Seaport Therapeutics (SPTX)?
Lana Gladstein reports stock options and preferred shares tied to Seaport Therapeutics common stock. Her holdings include multiple option grants and Series B Preferred Stock that can convert into common shares under specified terms and timelines, reflecting her equity-based compensation position.
What are the exercise prices and expirations of Lana Gladstein’s SPTX options?
Her options have exercise prices of $10.31, $7.39 and $3.05 per share. These options expire on February 23, 2036, December 28, 2034, and June 3, 2034, respectively, defining how long she can choose to purchase shares at those fixed prices.
How is Lana Gladstein’s Series B Preferred Stock in Seaport Therapeutics (SPTX) convertible?
Each share of Series B Preferred Stock is convertible into Seaport Therapeutics common stock on a one-for-3.1407 basis. It will automatically convert, without extra payment, into 33,515 common shares upon closing of the company’s initial public offering, and it has no expiration date.
What are the vesting terms of Lana Gladstein’s Seaport Therapeutics stock options?
One option grant is fully vested and exercisable, while others vest over four years. For one grant, one-quarter vested on June 6, 2025 with the rest in 36 monthly installments; another vests in 48 equal monthly installments after February 24, 2026, subject to continued service.